UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.96M | 37.84M | 27.48M | 24.22M | 20.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.96M | 37.84M | 27.48M | 24.22M | 20.25M |
| Cost of Revenue | 4.14M | 3.29M | 3.28M | 3.55M | 2.33M |
| Gross Profit | 46.82M | 34.55M | 24.20M | 20.67M | 17.92M |
| SG&A Expenses | 51.49M | 39.35M | 37.58M | 43.20M | 34.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.22M | 56.95M | 54.87M | 65.66M | 57.17M |
| Operating Income | -20.26M | -19.12M | -27.39M | -41.45M | -36.91M |
| Income Before Tax | -28.35M | -26.64M | -34.40M | -48.93M | -43.45M |
| Income Tax Expenses | -4.77M | -275.00K | -1.05M | 1.02M | 392.00K |
| Earnings from Continuing Operations | -23.57M | -26.36M | -33.35M | -49.94M | -43.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.57M | -26.36M | -33.35M | -49.94M | -43.84M |
| EBIT | -20.26M | -19.12M | -27.39M | -41.45M | -36.91M |
| EBITDA | -20.19M | -19.04M | -26.41M | -41.37M | -36.84M |
| EPS Basic | -0.47 | -0.54 | -0.69 | -1.05 | -0.92 |
| Normalized Basic EPS | -0.35 | -0.34 | -0.45 | -0.64 | -0.57 |
| EPS Diluted | -0.47 | -0.54 | -0.69 | -1.05 | -0.92 |
| Normalized Diluted EPS | -0.35 | -0.34 | -0.45 | -0.64 | -0.57 |
| Average Basic Shares Outstanding | 50.18M | 49.23M | 48.06M | 47.74M | 47.42M |
| Average Diluted Shares Outstanding | 50.18M | 49.23M | 48.06M | 47.74M | 47.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |